Capitalized Development Costs and a DSO Spike at Kestrel Industrial
Kestrel Industrial reports revenue of EUR 1,000 million, net income of EUR 100 million and cash flow from operations of EUR 60 million. The company capitalizes product development costs: EUR 120 million was capitalized this year, while amortization of the cumulative capitalized balance included in current expenses was EUR 60 million. Peers expense all development costs as incurred. Days sales outstanding rose from 60 to 85. Management attributes 25% revenue growth to 'multi-year contracts signed late in the year.' The tax rate is 25%, shares outstanding are 50 million, and the shares trade at 18 times reported EPS.
1. Restate net income, EPS and CFO as if development costs were expensed as incurred. What does the restatement imply about earnings quality?
Read the worked answer
Net income. Reported pre-tax income = 100 / 0.75 = EUR 133.3m. Under expensing, the year's cost is the EUR 120m cash outlay rather than the EUR 60m amortization, an incremental pre-tax expense of EUR 60m. Adjusted pre-tax = 73.3m; adjusted net income = 73.3 x 0.75 = EUR 55.0m (EPS 1.10 versus reported 2.00).
CFO. The cash left the business either way; capitalizing classifies it as investing. Adjusted CFO = 60 - 120 = -EUR 60m.
Earnings quality. The reported CFO/NI ratio is 0.60, already weak; on a comparable basis it is -1.1. Roughly 45% of reported net income and all of reported operating cash flow depend on the capitalization choice, not on operating performance. Two cautions before extrapolating: some development spending may genuinely create a multi-period asset, so the peer treatment is the benchmark for comparability rather than a claim that the spend is worthless; and the capitalized balance implies a five-year amortization profile that must be checked for impairment if the products slip.
2. Quantify the receivables implication of the DSO increase and assess management's explanation.
Read the worked answer
At 85 DSO, receivables = 85/365 x 1,000 = EUR 232.9m. At the prior 60 DSO they would be 164.4m, so about EUR 68.5m of the reported revenue is effectively uncollected relative to last year's terms, roughly 6.9% of revenue.
Assessment. The increase coincides with a claim that growth came from large contracts signed late in the year, which mechanically raises DSO at year-end if billing occurs at signing. That explanation is testable: check whether the receivables relate to a few named counterparties, whether they are unbilled contract assets, and whether they convert to cash in the first quarter. If the DSO rise is spread across the customer base, or if receivables are being factored or sold, the year-end revenue is of lower quality than the growth rate suggests. A 25-day deterioration is large enough that, combined with the negative adjusted CFO, the burden shifts to management to demonstrate collectibility rather than to the analyst to prove a problem.
3. Recommend how a valuation should incorporate these findings given the 18x reported EPS multiple.
Read the worked answer
Apply the multiple to a defensible earnings base, not to reported EPS.
- 18 x reported EPS of 2.00 gives EUR 36 per share.
- 18 x adjusted EPS of 1.10 gives EUR 19.80 per share.
The honest answer probably sits between the two, because the multiple itself should change: a company that expenses development and generates negative operating cash flow would not command a peer multiple. A workable approach is to value on a cash-based metric: use EBITDA or free cash flow after treating development spend as a cash cost, apply the peer multiple for those expensed peers, and then separately assess whether the capitalized pipeline has option value.
Also check the persistence items: if the 25% growth is genuine but receivable-heavy, forecast a working-capital drag that lowers near-term FCF. Present the valuation as a range and state explicitly that the EUR 36 figure is an artifact of an accounting policy choice, not a market price.